EGFR and non-small cell lung carcinoma: Similarly, the phase 3 trials NEJ026 [29] and ATLAS [30] revealed that intravenous bevacizumab plus erlotinib did not prolong OS compared with erlotinib alone in patients with metastatic EGFR-mutant NSCLC.